Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells (Q37347179)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 2009

Language	Label	Description	Also known as
English	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells	scientific article published on May 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

multiple drug resistance

1 reference

based on heuristic

inferred from title

Michael M. Gottesman

9

object named as

Michael M Gottesman

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Matthew D Hall

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Noeris K Salam

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jennifer L Hellawell

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Henry M Fales

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Caroline B Kensler

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Joseph A Ludwig

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Gergely Szakács

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

David E Hibbs

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

1 May 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Journal of Medicinal Chemistry

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

52

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

3191-3204

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Sunitinib: from rational design to clinical efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Pharmacophore-based discovery of ligands for drug transporters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Targeting multidrug resistance in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

The evolution of iron chelators for the treatment of iron overload disease and cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

GSK-3-selective inhibitors derived from Tyrian purple indirubins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

ABC transporters and inhibitors: new targets, new agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Mechanisms of cancer drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

Inhibition of RNA-dependent DNA polymerase of Rous sarcoma virus by thiosemicarbazones and several cations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

A history of the discovery and clinical application of antiviral drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

6 September 2017

In vitro cytotoxicity evaluation of some substituted isatin derivatives.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

14 September 2017

Synthesis of novel 5-substituted indirubins as protein kinases inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

14 September 2017

Synthesis and primary cytotoxicity evaluation of new 5-nitroindole-2,3-dione derivatives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

14 September 2017

Synthesis and primary cytotoxicity evaluation of new 5-bromo-3-substituted-hydrazono-1H-2-indolinones

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

14 September 2017

Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

28 September 2017

Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

28 September 2017

Chemical and biological properties of cytotoxic alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

28 September 2017

2-Acetylpyridine thiosemicarbazones. 1. A new class of potential antimalarial agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

28 September 2017

7 The Chemistry and Biological Activity of α -(N)-Heterocyclic Carboxaldehyde Thiosemicarbazones

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

28 September 2017

Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

26 June 2018

Interaction of DNA with anti-cancer drugs: copper-thiosemicarbazide system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

26 June 2018

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

2 September 2018

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

2 September 2018

SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2744114

2 September 2018

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/19397322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib maleate

1 reference

https://pubmed.ncbi.nlm.nih.gov/19397322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/19397322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/19397322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The action of nine chelators on iron-dependent radical damage

1 reference

https://pubmed.ncbi.nlm.nih.gov/19397322

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1021/JM800861C

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37347179&oldid=2245520695"